Clene (CLNN) Non Operating Interest Expenses (2020 - 2026)
Clene (CLNN) posted Non Operating Interest Expenses of $695000.0 for Q2 2026, down 6.84% on a QoQ basis from $746000.0 in Q4 2025, and up 2.36% year-over-year from $679000.0 in Q2 2025.
Analysis
Clene (CLNN) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends
Clene has reported Non Operating Interest Expenses for 7 years, with the latest figure at $695000.0 in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses rose 2.36% year-over-year to $695000.0 in Q2 2026; TTM through Jun 2026 was $2.8 million, a 1.98% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 34.01% from the prior year.
- Non Operating Interest Expenses was $695000.0 for Q2 2026 at Clene, down from $746000.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $1.3 million in Q2 2024, with the low at $516000.0 in Q4 2024.
- Average Non Operating Interest Expenses over 5 years is $899705.9, with a median of $857000.0 recorded in 2022.
- The sharpest annual moves came in 2022 and 2024: Non Operating Interest Expenses jumped 2788.46% in 2022, then tumbled 57.0% in 2024.
- Over 5 years, Non Operating Interest Expenses stood at $906000.0 in 2022, then surged by 32.45% to $1.2 million in 2023, then slumped by 57.0% to $516000.0 in 2024, then jumped by 44.57% to $746000.0 in 2025, then dropped by 6.84% to $695000.0 in 2026.
- The last three Non Operating Interest Expenses figures came in at $695000.0 (Q2 2026), $746000.0 (Q4 2025), and $649000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | - |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 23.78 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 2.90 Mn |
| 10 | Clene | 45.69 Mn | 45.69 Mn | 54,000.00 | 695,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 695,000.00 |
| Dec 31, 2025 | 746,000.00 |
| Sep 30, 2025 | 649,000.00 |
| Jun 30, 2025 | 679,000.00 |
| Mar 31, 2025 | 608,000.00 |
| Dec 31, 2024 | 516,000.00 |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.24 Mn |
| Dec 31, 2023 | 1.20 Mn |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 1.10 Mn |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | 906,000.00 |
| Sep 30, 2022 | 857,000.00 |
| Jun 30, 2022 | 751,000.00 |
| Mar 31, 2022 | 782,000.00 |
| Jun 30, 2021 | 26,000.00 |
| Mar 31, 2021 | 551,000.00 |
| Jun 30, 2020 | 190,000.00 |